Corcept Therapeutics (CORT) shares soared 5.5% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.3% gain over the past four weeks.The company’s sole marketed drug, Korlym, approved for treating Cushing's syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing’s syndrome is expected to be filed lat ...

Shares of Corcept Therapeutics (CORT) have gained 11.8% over the past four weeks to close the last trading session at $47.27, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $67.60 indicates a potential upside of 43%. The average comprises five short-term price targets ranging from a low of $45 to a high of $78, with a standard deviation of $13.32. While the lowest estimate indi ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate re ...

Our initiation report " "Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth" on September 15, 2024 became so long we had to save some content for this new report which focuses on the important near term news flow for Brown University Ab.ScB Civil Engineering/Urban Studies, Stanford University MBA, Morgan Guaranty Trust, Fiduciary Trust International ,Tanaka Capital Mgmt., Author "Digital Deflation" McGraw-Hill 2004. Appeared on CNBC and Bloomberg TV 40+ times. Manages the TANAKA Growth Fu ...

Corcept Therapeutics' (CORT) sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. The successful development and commercialization of its pipeline candidates will be an added boost to the company. Let's dig deeper. Reasons to Invest in CORT Stock Good Rank and Rising Estimates: Cor ...

Shares of Corcept Therapeutics (CORT) have gained 31.1% over the past four weeks to close the last trading session at $46.28, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $65.40 indicates a potential upside of 41.3%. The average comprises five short-term price targets ranging from a low of $45 to a high of $78, with a standard deviation of $12.46. While the lowest estimate in ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Our ...

Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it "is impressive and difficult to ignore." Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who ca ...

Corcept Therapeutics (CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.7% gain over the past four weeks. The company's sole marketed drug, Korlym, approved for treating Cushing's syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing's syndrome is expected to be filed in ...

Shares of Corcept Therapeutics Incorporated (CORT) have gained 46.2% in the past six months against the industry's decline of 2%. The company's sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. Factors Driving CORT Stock in the Given Time Frame Corcept has made steady progress ...